Company news

GeoVax Labs, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox

December 18, 2023

GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update

November 7, 2023

GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

October 29, 2023

GeoVax Receives Notice of Allowance for Marburg Vaccine Patent

October 8, 2023

GeoVax Receives Notice of Allowance for HIV Vaccine Patent

October 4, 2023

GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development

September 25, 2023

GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster

September 10, 2023

GeoVax to Present at the Emerging Growth Conference on September 6, 2023

August 28, 2023

GeoVax Receives Notice of Allowance for Malaria Vaccine Patent

August 27, 2023

GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

August 9, 2023

GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update

August 8, 2023

GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023

July 25, 2023

GeoVax Announces Issuance of Ebola Vaccine Patent

July 23, 2023

GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

July 19, 2023

GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference

June 27, 2023

GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates

May 30, 2023

GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update

May 3, 2023

GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses

April 16, 2023

GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate

April 5, 2023

GeoVax Reports 2022 Year-End Financial Results and Provides Corporate Update

March 22, 2023

GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial

February 14, 2023

GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines

February 7, 2023

GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers

February 6, 2023

GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors

December 6, 2022

GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update

November 8, 2022

GeoVax Announces Addition to Its Board of Directors

August 31, 2022

GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update

August 2, 2022

GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Sudan Ebolavirus Showing 100% Protection With a Single Immunization

July 27, 2022

GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update

July 25, 2022

GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development

June 12, 2022

GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules

May 24, 2022

GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China

May 23, 2022

GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update

April 26, 2022

GeoVax Announces Issuance of Cancer Vaccine Patent

March 21, 2022

GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials

March 13, 2022

GeoVax Reports 2021 Year-End Financial Results and Provides Corporate Update

March 8, 2022

GeoVax Announces Key Staff Appointments

March 6, 2022

GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update

February 22, 2022

GeoVax Announces Closing of $10 Million Private Placement

January 19, 2022

GeoVax Announces $10 Million Private Placement

January 13, 2022

GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial

January 12, 2022

GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer

January 10, 2022

GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster

December 14, 2021

GeoVax Announces Upcoming Presentations at Scientific Conferences

November 14, 2021

GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update

November 10, 2021

GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope's COVID-19 Vaccine

November 8, 2021

GeoVax Receives Notice of Allowance for Ebola Vaccine Patent

October 13, 2021

GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program

September 27, 2021

GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update

August 10, 2021

GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting

July 21, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 6 decks. Every deck is listed under its year.